title: [Sulodexide in the treatment of diabetic nephropathy].
abstract: Sulodexide (Vessel 2F, Italy) was given to 20 patients with diabetes mellitus type I with initial nephropathy. Urine excretion of albumin significantly fell in 18 patients and remained so in 15 patients 6 weeks after the drug discontinuation. Plasma total cholesterol tended to lowering. No changes were registered in hemostasis and carbohydrate metabolism. The authors propose combined administration of sulodexide and inhibitors of angiotensin-converting enzyme for treatment and prevention of diabetic nephropathy progression.
authors.forename: B L
authors.initials: BL
authors.lastname: Rasovskiĭ
authors.forename: A V
authors.initials: AV
authors.lastname: Tarasov
authors.forename: N Iu
authors.initials: NIu
authors.lastname: Trel'skaia
authors.forename: T I
authors.initials: TI
authors.lastname: Severina
authors.forename: E F
authors.initials: EF
authors.lastname: Chernykh
mesh_terms: D000328:Adult; D000704:Analysis of Variance; D002908:Chronic Disease; D003922:Diabetes Mellitus, Type 1 / Q000150:complications / Q000378:metabolism; D003928:Diabetic Nephropathies / Q000188:drug therapy* / Q000378:metabolism; D004341:Drug Evaluation; D005260:Female; D006025:Glycosaminoglycans / Q000627:therapeutic use*; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D008297:Male; D018709:Statistics, Nonparametric; D013997:Time Factors
chemical_list: D006025:Glycosaminoglycans; D007004:Hypoglycemic Agents; C007858:glucuronyl glucosamine glycan sulfate